Biotechnology News

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as...

Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env...

HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion...

U.S. FDA (Office of Orphan Products Development) grants Orphan Drug Designation for Sovateltide, a potential first-in-class therapy that could transform the treatment of Neonatal Hypoxic-Ischemic...

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment...

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 ...

CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observedCRB-913 was generally well tolerated with psychiatric...

Asimov delivered a high performance cell line for Sidewinder's bispecific antibody, achieving titers of over 10 g/L in a platform fed-batch process.

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,...

LEAWOOD, Kan., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc. today announced that it completed an INTERACT meeting with the U.S. Food and Drug Administration’s Center for Biologics Evaluation...